EGFR and non-small cell lung carcinoma: SKB-264 is currently approved in China for the treatment of locally advanced or meta3ic TNBC in adults who have received >2L of systemic therapy and EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC in adults who progressed after EGFR tyrosine kinase inhibitor therapy and platinum-based chemotherapy.